Skip to main content
Dr. Pinilla-Ibarz: Trial supports the use of nilotinib 300mg twice daily as front line therapy for CML
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Dr. Pinilla-Ibarz: Trial supports the use of nilotinib 300mg twice daily as front line therapy for CML
User login
Username
Password
Reset your password
concept
Lead
score
Chronic Myelogenous Leukemia
1
1
Specialty
Lead
score
Hematology-Oncology
1
1